Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options

Rhea-AI Filing Summary

Cabaletta Bio director Simon Mark received a grant of stock options as part of his compensation. The award covers 22,000 options to buy Cabaletta Bio common stock at an exercise price of $3.22 per share, expiring on June 8, 2036.

The options will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simon Mark

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,000 options Exercise price: $3.22 per share Expiration date: June 8, 2036 +2 more

5 metrics

Options granted 22,000 options Stock Option (Right to Buy) granted to director Simon Mark

Exercise price $3.22 per share Conversion or exercise price for the stock options

Expiration date June 8, 2036 Option term end date

Underlying shares 22,000 shares Common stock underlying the granted options

Holdings after grant 22,000 derivative securities Total stock options held following this transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 3.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"This option shall vest in full upon the earlier of June 9, 2027 or the next annual meeting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Mark

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.22	06/09/2026		A		22,000		(1)	06/08/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders.

	/s/ Michael Gerard, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cabaletta Bio (CABA) disclose in this Form 4 filing?

Cabaletta Bio disclosed that director Simon Mark received a grant of 22,000 stock options. These options give him the right to buy common shares at $3.22, expiring in 2036, as part of his board-level compensation package.

How many Cabaletta Bio (CABA) stock options were granted to Simon Mark?

Simon Mark was granted 22,000 stock options. Each option represents the right to purchase one share of Cabaletta Bio common stock at a fixed exercise price, providing equity-based incentive aligned with long-term shareholder interests and company performance.

What is the exercise price and expiration date of Simon Mark’s Cabaletta Bio options?

The options have an exercise price of $3.22 per share and expire on June 8, 2036. This means he can choose to buy shares at $3.22 any time after vesting until that expiration date, subject to the company’s equity plan rules.

When do Simon Mark’s Cabaletta Bio stock options vest?

The stock options vest in full on the earlier of June 9, 2027 or the date of Cabaletta Bio’s next annual stockholder meeting. Full vesting is required before he can exercise the options to purchase underlying common shares.

Is this Cabaletta Bio Form 4 a stock purchase or sale by Simon Mark?

This Form 4 reports a grant of stock options, not an open-market share purchase or sale. It reflects a compensation award giving future rights to buy Cabaletta Bio common stock, rather than an immediate cash transaction in the company’s shares.